Reading the evidence
Conflicts of Interest in Research: How Funding and Allegiance Shape Results
AR
· 10 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
- What counts as a conflict of interest?
- Does industry funding change results?
- How does sponsorship bias work if the methods look sound?
- What about literatures from a single laboratory?
- How do you find the disclosures in a paper?
- What should you do with a conflict once you have found it?
- Frequently asked questions
A conflict of interest in research is any financial or personal stake that could influence how a study is designed, analysed or reported. The best evidence, a Cochrane review by Lundh and colleagues, found that industry-sponsored drug and device studies more often report favourable efficacy results and conclusions than independently funded ones. Standard risk-of-bias checks do not explain the gap. A conflict does not make a result wrong. It is a reason to look harder at the design, the comparator and whether anyone independent has reproduced the finding.

What counts as a conflict of interest?
Most disclosure systems focus on money, but the incentives that shape research are broader.
| Type | Examples | Usually disclosed? |
|---|---|---|
| Funding | The sponsor paid for the study | Yes, in a funding statement |
| Employment and equity | Authors employed by, or holding shares in, the sponsor | Yes, in affiliations and the conflict statement |
| Consulting and fees | Advisory boards, speaker fees, travel | Usually, on a disclosure form |
| Intellectual property | Patents or licences on the compound | Inconsistently |
| Commercial development | The compound is being developed by a company linked to the authors | Sometimes, in the introduction or affiliations |
| Intellectual allegiance | A group that discovered a compound and has built a career on it | Almost never |
The last row is the hardest to see and, for several compounds on this site, the most relevant.
Does industry funding change results?
Systematic reviews of the question have reached the same answer for more than two decades.
- Bekelman and colleagues, 2003. About a quarter of investigators had industry affiliations, and roughly two thirds of academic institutions held equity in start-ups that sponsored research at the same institutions. Across eight analyses covering 1,140 studies, industry sponsorship was associated with pro-industry conclusions, with a pooled odds ratio of 3.60. Sponsorship was also associated with restrictions on publication and data sharing.
- Lexchin and colleagues, 2003. Across 30 studies, drug-company funding was associated with outcomes favouring the sponsor (odds ratio 4.05) and with a lower chance of publication. None of the 13 studies that examined methods found industry trials to be of poorer quality. The authors pointed to the choice of comparator and to publication bias as explanations.
- Lundh and colleagues, Cochrane, 2017. Across 75 papers, industry-sponsored studies more often had favourable efficacy results (risk ratio 1.27, 95% CI 1.17 to 1.37) and favourable conclusions (1.34, 1.19 to 1.51). For harms, the estimate was 1.37 with an interval from 0.64 to 2.93, too imprecise to conclude anything. Industry studies were more often at low risk of bias from blinding. Their conclusions agreed with their own results less often (0.83, 0.70 to 0.98).
That combination is the important part. Industry trials were not worse by the usual quality checklists, and in blinding they were better. The bias sits somewhere the checklists do not look.
How does sponsorship bias work if the methods look sound?
Through decisions made before and after the data, rather than errors in collecting them:
- The question. Which population, which outcome, which duration. A trial can be impeccable and still be designed to answer a question its sponsor expected to win.
- The comparator. Placebo rather than the best existing drug, or an active comparator at a weak dose. Lexchin's review named comparator choice directly.
- The analysis and framing. Which outcomes go in the abstract, and how a borderline result is described.
- Publication. Whether, when and where a result appears; see publication bias explained.
Two large trials discussed on this site show what disclosure looks like in practice. TRIUMPH-1, the phase 3 retatrutide obesity trial, was funded by Eli Lilly. Seven of the eleven named authors list Lilly as their affiliation. The RECONNECT trials of bremelanotide were funded by Palatin Technologies and AMAG Pharmaceuticals. Both are randomised, double-blind and placebo-controlled, and sponsor funding is how almost every drug reaches phase 3. Neither fact undermines them. They tell a reader who chose the outcomes and who controls the data. Retatrutide is investigational and approved nowhere. Bremelanotide is approved in the United States as Vyleesi for one indication, and research-chemical PT-141 is not that medicine.
What about literatures from a single laboratory?
Several compounds sold as research chemicals have literatures dominated by one group, often the group that discovered them. A PubMed title-and-abstract search run on 25 October 2026 gives a rough measure. Author-name searches are imperfect, and the totals include reviews.
| Compound | PubMed records | Records listing the originating group's lead author | Share |
|---|---|---|---|
| BPC-157 | 228 | 174 listing Sikiric P (Zagreb) | About 76% |
| Epitalon | 164 | 98 listing Khavinson V | About 60% |
| Semax | 210 | 97 listing Myasoedov NF | About 46% |
BPC-157. The compound was taken into early clinical work for inflammatory bowel disease under industry codes. A 2006 rat Achilles paper from the Zagreb group says so in its own abstract, naming PL 14736 and the company Pliva. Recent papers from the group carry statements that the authors declare no conflicts of interest. That may be accurate on a financial disclosure form, which asks about money and not about a career spent on one molecule. A systematic review by Vasireddi and colleagues found 36 eligible studies of BPC-157 in orthopaedic sports medicine: 35 preclinical and one clinical. One of the most cited exceptions to the Zagreb pattern is Chang and colleagues' tendon-cell work from Taiwan. BPC-157 is approved nowhere; see BPC-157 musculoskeletal research.
Epitalon. The widely quoted telomerase result comes from a short 2003 report by Khavinson and colleagues: in telomerase-negative human fetal fibroblasts, the peptide induced telomerase expression and activity and telomere elongation. An independent cell study by Al-Dulaimi and colleagues in 2025 reported telomere lengthening too, through different mechanisms in normal and cancer cells. Independent replication of that kind is what a single-source literature needs. It is still cell culture. Epitalon is approved nowhere, and is sold here only as laboratory research material; see Epithalon and the pineal gland.
Semax. Semax is a registered medicine in Russia and approved nowhere else. Its clinical literature is largely Russian, and much of it predates modern trial reporting standards; see Semax and stroke research and, for why open-label studies inflate effects, open-label vs placebo-controlled.
None of this implies misconduct. A group that discovers a molecule will naturally study it most. But its papers share methods, models, reagents and assumptions, and its members have strong reasons to believe the compound works. Consistency between their papers is weaker evidence than consistency between independent groups.
How do you find the disclosures in a paper?
| Where to look | What it tells you | Its limit |
|---|---|---|
| Author affiliations | Employees of the sponsor or developer | Consultants and shareholders do not show here |
| Funding statement | Who paid | "No specific funding" can hide institutional or in-kind support |
| Conflict of interest statement, often shown below the abstract on PubMed | Declared financial ties | Self-declared, and limited to what the form asks |
| Disclosure forms, often based on the International Committee of Medical Journal Editors form | Fees, grants, patents, by author | Usually in supplementary files |
| Acknowledgements | Medical writers, statistical support from the sponsor | Easily skipped |
| Trial registration | Sponsor and responsible party, who controls the data | Only for registered trials |
| Introduction and methods | Development codes, licensing, compound supplied by a company | Not labelled as a conflict |
How to read a PubMed abstract shows where these fields sit on a PubMed record. Older papers, and many from journals outside the main indexing systems, have no conflict statement at all. Missing does not mean none.
What should you do with a conflict once you have found it?
Do not discard the study; most drug evidence comes from sponsors, and their trials are often the best conducted. Instead:
- Check that the comparator was fair and the primary outcome matched the registration.
- Read the results table, not only the abstract's conclusion. Lundh found conclusions drift from results more often in sponsored work.
- Look for independent replication, by a group with no stake in the compound.
- For preclinical literatures, ask whether the effect has been seen outside the originating laboratory at all.
For what cell and animal results can and cannot show, see in vitro vs in vivo; for the wider limits of a single study, how to read a peptide study. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Does industry funding mean a study is biased? Not necessarily. Industry trials are often large, blinded and carefully run, and Lundh's review found them better on blinding than independent trials. The concern is systematic: across many studies, sponsored work reaches favourable results and conclusions more often, for reasons quality checklists do not capture. Judge each study by its comparator, outcomes and replication.
What is a non-financial conflict of interest? A stake that is not money: a theory a researcher has championed, a compound a laboratory discovered, a career or reputation built on one finding. These are rarely declared, because disclosure forms ask about payments. They matter most where one group produces most of a compound's literature.
Why do some papers have no conflict of interest statement? Requirements to publish one were adopted gradually, journal by journal, and some journals still apply weaker standards. Some older papers on BPC-157, Epitalon and Semax carry none. Absence of a statement is absence of information, not a declaration that no conflict existed.
How can I tell if a finding has been independently replicated? Look at the author lists and affiliations of every paper reporting it. If they all share a senior author, institution or funder, the finding has not been independently replicated, however many papers there are. Systematic reviews sometimes comment on this directly; when they do not, count the groups yourself.
Selected Research References
- Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017;2:MR000033. pubmed.ncbi.nlm.nih.gov/28207928
- Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-465. pubmed.ncbi.nlm.nih.gov/12533125
- Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170. pubmed.ncbi.nlm.nih.gov/12775614
- Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. pubmed.ncbi.nlm.nih.gov/31599840
- Krivic A, Anic T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. pubmed.ncbi.nlm.nih.gov/16583442
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495. pubmed.ncbi.nlm.nih.gov/40756949
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. pubmed.ncbi.nlm.nih.gov/21030672
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. pubmed.ncbi.nlm.nih.gov/12937682
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. pubmed.ncbi.nlm.nih.gov/40908429
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
